Anticoagulation-Free Pediatric Extracorporeal Membrane Oxygenation: Single-Center Retrospective Study
- PMID: 36883843
- DOI: 10.1097/PCC.0000000000003215
Anticoagulation-Free Pediatric Extracorporeal Membrane Oxygenation: Single-Center Retrospective Study
Abstract
Objectives: To analyze hemorrhage and thrombosis data related to anticoagulation-free pediatric extracorporeal membrane oxygenation (ECMO).
Design: Retrospective cohort study.
Settings: High-volume ECMO single institution data.
Patients: Children (0-18 yr) supported with ECMO (>24 hr) with initial anticoagulation-free period of greater than or equal to 6 hours.
Interventions: None.
Measurements and main results: Utilizing consensus American Thoracic Society definitions for hemorrhage and thrombosis on ECMO, we evaluated thrombosis and associated patient and ECMO characteristics during anticoagulation-free period. Thirty-five patients met inclusion criteria from 2018 to 2021 having a median age (interquartile range [IQR]) of 13.5 months (IQR, 3-91 mo), median ECMO duration of 135 hours (IQR, 64-217 hr), and 964 anticoagulation-free hours. Increased RBC transfusion needs were associated with longer anticoagulation-free periods ( p = 0.03). We identified 20 thrombotic events: only four during the anticoagulation-free period and occurring in three of 35 (8%) patients. Compared with those without thrombotic events, anticoagulation-free clotting events were associated with younger age (i.e., 0.3 mo [IQR, 0.2-0.3 mo] vs 22.9 mo [IQR, 3.6-112.9 mo]; p = 0.02), lower weight (2.7 kg [IQR, 2.7-3.25 kg] vs 13.2 kg [5.9-36.4 kg]; p = 0.006), support with lower median ECMO flow rate (0.5 kg [IQR, 0.45-0.55 kg] vs 1.25 kg [IQR, 0.65-2.5 kg]; p = 0.04), and longer anticoagulation-free ECMO duration (44.5 hr [IQR, 40-85 hr] vs 17.6 hr [IQR, 13-24.1]; p = 0.008).
Conclusions: In selected high-risk-for-bleeding patients, our experience is that we can use ECMO in our center for limited periods without systemic anticoagulation, with lower frequency of patient or circuit thrombosis. Larger multicentered studies are required to assess weight, age, ECMO flow, and anticoagulation-free time limitations that are likely to pose risk for thrombotic events.
Copyright © 2023 by the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies.
Conflict of interest statement
Dr. Said received funding from the Children’s Discovery Institute Faculty Development Award at Washington University in St. Louis. The remaining authors have disclosed that they do not have any potential conflicts of interest.
Comment in
-
Realizing Potential: Pediatric Extracorporeal Membrane Oxygenation Needs Common Adverse Event Definitions to Improve Outcomes.Pediatr Crit Care Med. 2023 Jun 1;24(6):528-530. doi: 10.1097/PCC.0000000000003270. Epub 2023 Jun 1. Pediatr Crit Care Med. 2023. PMID: 37260339 Free PMC article. No abstract available.
References
-
- Penk JS, Reddy S, Polito A, et al.: Bleeding and thrombosis with pediatric extracorporeal life support: A roadmap for management, research, and the future from the Pediatric Cardiac Intensive Care Society: Part 1. Pediatr Crit Care Med. 2019; 20:10341027–10341039
-
- Dalton HJ, Reeder R, Garcia-Filion P, et al.: Factors associated with bleeding and thrombosis in children receiving extracorporeal membrane oxygenation. Am J Respir Crit Care Med. 2017; 196:762–771
-
- Penk JS, Reddy S, Polito A, et al.: Bleeding and thrombosis with pediatric extracorporeal life support: A roadmap for management, research, and the future from the Pediatric Cardiac Intensive Care Society: Part 2. Pediatr Crit Care Med. 2019; 20:1034–1039
-
- McMichael ABV, Ryerson LM, Ratano D, et al.: ELSO adult and pediatric anticoagulation guidelines. ASAIO J. 2021; 9000
-
- Takagaki M, Yamaguchi H, Ikeda N, et al.: Post-cardiotomy venovenous extracorporeal membrane oxygenation without heparinization. Gen Thorac Cardiovasc Surg. 2019; 67:982–986
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
